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AIM: Heat shock proteins (HSPs) have essential roles in a number of pathophysi-
ologic conditions including carcinogenesis and represent a group of novel molecular
markers in cancer management.  The aim of this study is to explore the expression
status of HSPs in bladder urothelial carcinoma (BUC) patients.
METHODS: The immunohistochemical staining of HSP10, HSP27, HSP60, HSP70,
and HSP90 were done in 46 vesical BUC patients with different grades (G) and stages
(T).  Statistical analyses were performed to determine whether there was any correla-
tion between tumoral HSP expression and both G and T of tumors.
RESULTS: We found a significant correlation between high grading (G ≥ 2) and tu-
mor tissues positive for HSP10 and HSP90 staining (P < 0.001).  Moreover, the positive
immunostaining of HSP70 was significantly linked with G3 tumors (P < 0.001), but
HSP27 or HSP60 expression was not related with the G level of tumor.  There was a
significant correlation between higher T stages (T > 1) and tumor tissues expressing
HSP70 (P < 0.001); in contrast, the number of tumor cells having HSP60 expression
was significantly decreased in T > 1 tumors (P < 0.005).  No relationship was found
between tumoral T status and HSP10, HSP27 and HSP90 expression.  Finally, we found
a significant correlation between the high-graded (G ≥ 2) neoplasms and the percenta-
ge of tumoral cells positive for HSP10, HSP27, HSP70, or HSP90 (P < 0.005).
CONCLUSION: This is the first report to show the presence of HSP10 in bladder cancer
tissues, with its expression correlated to the tumoral grading.  These data may also be
valuable for developing new molecular anti-cancer therapies.
Journal of Cancer Molecules 2(2): 73-77, 2006.
Keywords:
bladder cancer
carcinogenesis
clinical outcome
molecular markers
Introduction
Urothelial carcinoma of bladder (BUC2) is the fifth most
common malignancy in Western countries [1].  It accounts
for 5% of all diagnosed cancers and the peak of incidence is
between the fifth and seventh decades.  The medical as-
sessment of BUC includes clinical and histological diagno-
ses with the grading (G) and staging (T) of primary tumour
by the pathological materials obtained through endoscopy
and/or bladder resection [2,3].  The therapeutic approach for
individual patients is currently guided by histology-based
prognostic factors, although more recently, a number of
experimental and clinical studies are exploring novel
molecular predictors.
The  significance of the  researches of heat shock proteins
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(HSPs) in clinical management of tumoral patients is now
expanding.  These molecules play a major role in protecting
cells against damage in stress conditions, but they also have
essential roles under a number of physiological conditions
[4].  Experimental data suggest that they may suppress
apoptosis and thus promote tumorigenesis [5].  Neverthe-
less, some HSPs may have a pro-apoptotic action as well as
play important roles in the immune response against cancer
[6].
HSPs are a family of highly conserved proteins, firstly de-
scribed over 40 years ago [7].  HSP10, HSP60 and HSP90 are
constitutively expressed in mammalian cells, while HSP27
and HSP70 are induced by several stresses [5].  HSPs have
different functions inside normal cells, such as prevention of
the aggregation of denatured polypeptides [8], interorganel-
lar transport [5], and antigen processing and presentation [9].
Moreover, most of them have been proposed to regulate
apoptosis.  For example, HSP27, HSP70 and HSP90 were
considered as antiapoptotic, since they were able to bind to
some pro-apoptotic molecules, including cytochrome c and
Apaf [10].  In contrast, HSP10 and HSP60 were suggested as
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proapoptotic [11], although the exact role(s) of the latter has
still not been fully elucidated [12].
The clinical significance of HSP expression in bladder
cancers has not been entirely investigated yet.  Storm et al.
were the first to examine the diagnostic and prognostic sig-
nificance of HSP27 expression, finding that it did not provide
a predictive biologic marker in some genitourinary tumors,
among them bladder cancer [13].  More recently, Syrigos et
al. have shown that HSP70 was frequently overexpressed in
vesical tumoral cells and it could be a useful biochemical
marker [14].  Lebret et al. have demonstrated that high levels
of HSP90 and a low expression of HSP60 might have a prog-
nostic relevance in patients with bladder carcinoma, having
HSP60 a practical use as a prognostic marker to identify
patients for whom local treatment would be insufficient [15].
In the present study, we investigate the expression of five
HSPs, specifically HSP10, HSP27, HSP60, HSP70, and HSP90,
in a series of bladder BUC with different G and T.  Our data
partially agree with previous results, some other is new.
Materials and Methods
Specimen collection
We collected biopsies from 46 consecutive BUC patients
of our pathological archives during a period of 24 months.
All tumors were primary.  The G and T of these cases were
determined according to the World Health Organiza-
tion/International Society of Urological Pathology
(WHO/ISUP) guidelines [16] and are shown in Table 1.
Although eight patients with invasive disease subsequently
underwent a cystectomy in the same hospital, we used the
first removed biopsies for our experiments; we obtained
follow-up data at one-year from only 3 out of 8 cases and
these patients were free of local recurrence.  We have not
had any follow-up data from the other patients.  All the tis-
sues were formalin-fixed and paraffin-embedded for
pathologic diagnoses.  Moreover, we collected 10 samples of
normal vesical mucosa from our anatomical archives.  The
latter were Bouin-fixed and paraffin-embedded.  We obtained
sections with a thickness of 4-5 µm from all specimens for
immunohistochemistry.
Immunohistochemistry
Immunohistochemistry (IHC) was performed by a strep-
tavidin-biotin complex method using LSAB2 kit (DAKO Co.,
Carpinteria, CA, USA).  The used primary antibodies includ-
ed anti-HSP10 (dilution 1:400, Cat. No. SPA-110, StressGen
Biotechnologies Co., Victoria, BC, Canada), HSP27 (dilution
1:200, Cat. No. SC-13132, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), HSP60 (dilution 1:400, Cat. No. H4149, Sig-
ma Co., Saint Louis, MI, USA), HSP70 (dilution 1:200, Cat. No.
SC-24, Santa Cruz Biotechnology) and HSP90 (dilution 1:200,
Cat. No. SC-13119, Santa Cruz Biotechnology).  After depar-
affination and rehydratation, the sections were incubated for
10 min with protein blocking agent (DAKO).  Subsequently,
the primary antibodies were added to the sections.  Non-
immune rabbit serum was used for negative controls, and
appropriate   positive   controls   were   done  simultaneously.
Table 1: Tumoral stages and grades of studied BUC
patients, determined according to the WHO/ISUP clas-
sification
Ta/Tis* T1 > T1 Total
G1 12 8 4 24
G2 6 6 2 14
G3 2 4 2 8
Total 20 18 8 46 
*15 of them were Ta and 5 were Tis.
Diaminobenzidine was used as chromogen and hematoxylin
aqueous formula was used as counterstaining.  The IHC
results were assessed by two independent observers (F.
Cappello and F. Rappa).
Quantitative analysis of immunohistochemistry
The tissue expression of each HSP was quantified by a
computer-assisted image analysis system Colourvision 1.7.6
(Improvision, Coventry, UK).  For each biopsy, the tissue was
systematically assessed, in two non-serial sections, on basis
of red, green and blue (RGB) colour balance.  In the begin-
ning of each session, the image analysis system was stan-
dardised using the same section of tissue stained for the
HSP to ensure reproducibility of analysis.  The digitised im-
age of the standard section was used to interactively sample
an example of the positive staining and the system was then
allowed to select all the pixels of the same RGB colour bal-
ance (i.e., positive staining) within the image.  The area of the
examined tissue was then delineated interactively and the
percentage of positive staining within the tissue was deter-
mined; the colour balance and perceptual staining value was
recorded for future sessions.  In the beginning of each sub-
sequent session, the image analyser was calibrated using
this section and adjusted to within ± 5% of the original pixel
reading. Once the system had been calibrated using the
‘standard’ slide, the test sections were analysed, using the
same parameters. Each tissue section was analysed on two
separate occasions by two independent observers (F. Cap-
pello and F. Rappa), and mean values of the duplicate obser-
vation data were analysed using Mann Whitney U test.  A
value of P < 0.05 was considered significant.
Statistical analyses
We analysed the significance of the data using the Student
t test (P < 0.05).  A one-way analysis of variance was used to
determine the correlation between: (a) tumoral expression of
HSPs and tumoral G, (b) tumoral expression of HSPs and
tumoral T, and (c) the number of HSPs-expressing tumoral
cells in each tumor and tumoral G.
Results
Expression of HSPs in normal uroepithelium and BUC
We found a variable number of tumors positive for each
HSP (Figure 1 and Table 2).  Most of the cases were positive
for HSP27 (91.3%), while HSP60 and HSP70 (21.7%) resulted
to have the smallest amount of expression.  In particular, all
HSPs were present at the cytoplasmic level in tumor cells of
BUC with different grades.  Interstitial stroma was commonly
negative.  Additionally, a variable number of normal vesical
mucosa expressed HSPs in the cytoplasm above all in the
superficial layers of uroepithelium.
Correlation between expression of HSPs and malignancy of
BUC
We researched a correlation between tumor HSP expres-
sion and tumoral G, and we obtained a significant correlation
between highly graded (G ≥ 2) neoplasms and tumoral
HSP10 and HSP90 expression (P < 0.001, Table 3).  Moreover,
the presence of HSP70 expression was significantly linked to
tumors with G = 3 (P < 0.001, Table 3).  In contrast, the BUC
tissues positive for HSP27 or HSP60 staining did not show
any relationship with G (Table 3).
On the other hand, the expression of HSP60 was signifi-
cantly decreased in BUC tissues with T > 1 (P < 0.005, Table
4).  Indeed, in low-staged tumors, there were more cases
expressing HSP60 than in high-staged ones.  In addition, a
significant correlation was found between high T tumors (T >
1) and HSP70 expression (P < 0.001, Table 4).  No correlatio
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Figure1: Panel of representative pictures of the IHC results of HSPs.  The number of tumor tissues positive for each HSP was variable.  Positive
immunostaining was noted at the cytoplasm of tumor cells.  And also a variable number of normal specimens expressed HSPs in cytoplasm, above
all in the superficial layers.  N: normal urothelium; G1, G2 and G3: BUC with different grades of differentiation.  Original magnification: 40 ×.
Table 2: Number and percentage of the normal bladder and BUC specimens with IHC positive for HSPs
HSP10 HSP27 HSP60 HSP70 HSP90
Normal bladder 5/10 (50%) 10/10 (100%) 3/10 (30%) 3/10 (30%) 7/10 (70%)
BUC 32/46 (69.6%) 42/46 (91.3%) 10/46 (21.7%) 10/46 (21.7%) 34/46 (73.9%)
Table 3: Relationships between tumoral expression of HSPs and tumoral grading (G) in BUC
HSP10 HSP27 HSP60 HSP70 HSP90
N 5/10 (50%) 10/10 (100%) 3/10 (30%) 3/10 (30%) 7/10 (70%)
G1 10/24 (41.7%) 20/24 (83.3%) 4/24 (16.7%) 2/24 (8.3%) 12/24 (50%)
G2 14/14 (100%)a 14/14 (100%) 4/14 (28.6%) 2/14 (14.3%) 14/14 (100%)a
G3 8/8 (100%)a 8/8 (100%) 2/8 (25%) 6/8 (75%)b 8/8 (100%)a
aP < 0.001 if G ≥ 2 vs. G = 1.
bP < 0.001 if G = 3 vs. G ≤ 2.
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Table 4: Relationships between tumoral expression of HSPs and tumoral staging (T) in BUC
HSP10 HSP27 HSP60 HSP70 HSP90
N 5/10 (50%) 10/10 (100%) 3/10 (30%) 3/10 (30%) 7/10 (70%)
Ta/Tis 14/20 (70%) 18/20 (90%) 6/20 (30%) 2/20 (10%) 14/20 (70%)
T1 12/18 (66.7%) 16/18 (88.9%) 4/18 (22.2%) 2/18 (11.1%) 14/18 (77.8%)
> T1 6/8 (75%) 8/8 (100%) 0/8 (0%)a 6/8 (75%)b 6/8 (75%)
aP < 0.005 if T > 1 vs. T ≤ 1.
bP < 0.001 if T > 1 vs. T ≤ 1.
Table 5: Relationships between the grading (G) of BUC and the ratio of HSP-positive tumor cells in BUC tissues
HSP10 HSP27 HSP60 HSP70 HSP90
N 5% (0-10%) 10% (0-20%) 1% (0-2%) 5% (0-10%) 10% (0-20%)
G1 15% (0-20%) 45% (20-90%) 1% (0-2%) 15% (0-25%) 20% (0-30%)
G2 85% (60-95%)a 90% (75-100%)a 1% (0-3%) 80% (60-95%)a 90% (60-100%)a
G3 95% (65-100%)a 95% (80-100%)a 1% (0-2%) 90% (60-100%)a 95% (80-100%)a
aP < 0.005 if G ≥ 2 vs. G = 1.
between the expression of HSP10, HSP27 or HSP90 and T
levels of BUC was noted.
Correlation between HSP-positive tumor cell number and
BUC grading
We analysed if the existence of a statistical correlation be-
tween the tumoral G and the number of tumor cells positive
for each HSP immunostaining.  We found a significant asso-
ciation of the high grades (G ≥ 2) of BUC with the percentage
of tumor cells positive for HSP10, HSP27, HSP70, and HSP90,
but not for HSP60 (P < 0.005, Table 5).
  
Discussion
The study of the levels of HSPs in several tumours is a
topic of growing interest.  An increased expression of HSP27
has been reported in a number of tumours, such as breast
carcinoma [17], endometrial cancer [18] and leukemia [19].
High levels of HSP70 have been detected in osteosarcoma
[20] and renal tumor cells [21].  In addition, HSP90 has been
shown to be overexpressed in lung cancer [22] and breast
carcinoma [23].  In recent studies, we researched the ex-
pression status of HSP60 and HSP10 during exocervical
[24,25], colonic [25,26] and prostatic carcinogenesis [27],
discovering that their expression increased from normal
through dysplastic to neoplastic tissues.  Other studies con-
firmed our results [28,29].  Commonly, high expression of
HSPs has been associated with cancer metastases, poor
prognoses and resistance to chemotherapy and radiation
therapy [30-33].
At the present time, only few researches have been fo-
cusing on HSP expression in BUC.  The first of these papers
focused on the diagnostic and prognostic significance of
HSP27 in a series of vesical (as well as prostatic) cancers
[13].  The authors did not find any correlation between the
expression of HSP27 and (i) the degree of histologic differen-
tiation, (ii) the T stage,  (iii) lymph node involvement, (iv)
local tumor recurrence, (v) tumor metastases, and
(vi) survival, and therefore concluded that tumor HSP27
overexpression had neither a diagnostic nor prognostic sig-
nificance.  More recently, another study investigated the
expression of HSP90 (as well as IL-6 and IL-10) in a series of
superficial and invasive bladder cancers [34].  Interestingly,
it was found that HSP90 was expressed in 92.9% of exam-
ined tumors; moreover, the invasive samples contained sig-
nificantly higher levels of HSP90 than the superficial ones.
The authors concluded that this protein could have inde-
pendent functional roles, also representing an immunogenic
target for antitumoral response.
The above described results were confirmed by Lebret et
al. who studied the presence and expression of HSP27,
HSP60, HSP70 and HSP90 in a wide series of bladder malig-
nancies [15].  In particular, they looked for the existence of a
correlation between HSP expression and tumoral T and G,
other than prognosis.  Although they did not find any corre-
lation of the expression of HSP27 and HSP60 with tumoral T,
the HSP60 and HSP90 levels were found to associate with
the outcome of the patients with superficial bladder carci-
noma.  They stated that loss of HSP60 expression, together
with persistent HSP90 overexpression, might have a prog-
nostic relevance in BUC management.  Finally, Syrigos et al.
researched the expression of HSP70 in a series of BUC,
finding that this molecule was frequently overexpressed in
advanced grades of bladder cancer and suggesting its role
as biochemical marker [14].
In the present work, we studied the expression of five
HSPs in a series of BUC tissues.  We have shown that HSP10
but not HSP60 increased from normal through dysplastic to
neoplastic specimens.  Down-regulation of HSP60 in bladder
carcinogenesis was a novel but not utterly original result.  It
was reported that 39 out of 42 (> 90%) urothelial cancer tis-
sues exhibited HSP60 expression from a mean of 77% of
cancer cells [15], whereas in our series we found that only ~
20% of BUC patients had HSP60 expression from < 2% of
cancers cells (Table 2).  This discordance could be due to
the biological variability of the tumours present in different
series.  Nevertheless, in agreement with Lebret [15], we ob-
served that HSP60 expression significantly decreased in the
tumors with T > 1 and we consider the latter as the most
notable data.  Recently, we were the first to notice a similar
down-regulation of HSP60 level during bronchial carcino-
genesis.  HSP60 was present and expressed by basal and
columnar elements of normal and hyperplastic bronchial
mucosae, while gradually disappeared ongoing towards
airway metaplasia, dysplasia and cancer [35].  We supposed
that the HSP60 levels during carcinogenesis may depend on
the expression of other proteins probably involved in the
pro-apoptotic pathways [36], but we are still far from recog-
nizing the underlying molecular mechanisms.
We presently also detected a small number of cases posi-
tive for HSP70.  This HSP70 expression was significantly
associated with the neoplasms with a higher T status (T > 1),
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in accordance with the results obtained by Syrigos and col-
leagues [14].  In addition, we indicated the presence of a
correlation between the tumoral G and the number of tumour
cells positive for four HSPs.  The significant correlation was
demonstrated between the high-grading (G ≥ 2) neoplasms
and the ratio of tumour cells positive not only for HSP70 and
HSP90, as already reported [14,15,34], but also for HSP10
and HSP27 (Table 5).
Noteworthily, the obvious IHC result for HSP10, as also
demonstrated elsewhere [25,27,29], suggest that this protein
may have a diagnostic and prognostic marker role in BUC
management.
In conclusion, our present data confirm that tumoral
HSP90 and HSP70 expression is correlated with tumoral T
status as already shown by Lebret [15] and Syrigos [14],
while HSP60 expression is inversely correlated with tumoral
T in accordance with Lebret [15].  We showed a correlation
between the tumoral G and the number of tumour cells posi-
tive for HSP27; nevertheless, we did not find any correlation
between the ratio of HSP27-positive tumor cells and the tu-
mor status with both high G and high T.  Since this result
was not in agreement with the study of Storm [13], perhaps
due to the phenotypic variability of the tumors, our sugges-
tion is to reconsider this datum in a wider series.  The pre-
sent report is the first paper to study the HSP10 expression
in bladder carcinoma tissues.  It would be interesting to con-
sider the value of this tumoral HSP10 expression in the clini-
cal follow-up of BUC, but we have not yet these data.  We
also hypothesise that the mitochondrial chaperones HSP60
and HSP10, which are functionally related in normal cells,
have distinct roles in BUC pathogenesis because of their
different expression status in BUC tissues.
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